PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males

Gan and Lee Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Diabetes Mellitus

Treatments: Drug: Gan & Lee Insulin Lispro Injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT04235439

GL - LSP - 1006

Details and patient eligibility

About

Primary objective:

To demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of Gan & Lee Insulin Lispro Injection with both EU - approved Humalog® and US - licensed Humalog® (Reference Products) in healthy male subjects

Secondary objectives:

To compare the PK and PD parameters of the three insulin lispro preparations

To evaluate the single dose safety and local tolerability of the three insulin lispro preparations

Enrollment: 36 patients

Sex: Male

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Signed and dated informed consent obtained before any trial related activities. Trial related activities are any procedures that would not have been done during normal management of the subject
2. Healthy male subjects
3. Age between 18 and 64 years, both inclusive
4. Body Mass Index (BMI) between 18.5 and 29.0 kg/m^2, both inclusive
5. Fasting plasma glucose concentration <= 5.5 mmol/L (100 mg/dL) at screening
6. Considered generally healthy upon completion of medical history and screening safety assessments, as judged by the Investigator

Exclusion criteria

1. Known or suspected hypersensitivity to IMP(s) or related product
2. Previous participation in this trial. Participation is defined as randomized
3. Receipt of any medicinal product in clinical development within 30 days before randomization in this trial
4. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
5. Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator
6. Any history or presence of clinically relevant comorbidity, as judged by the Investigator
7. Signs of acute illness as judged by the Investigator
8. Any serious systemic infectious disease during four weeks prior to first dosing of the trial drug, as judged by the Investigator
9. Clinically significant abnormal screening laboratory tests, as judged by the Investigator
10. Elevation of serum ALT> 10% above the ULN, or elevation of serum AST or serum bilirubin >20% above the ULN. (Note: Elevation of bilirubin is considered acceptable in case of Gilbert's disease and should be evaluated in clinical context)
11. Elevation of serum creatinine > ULN, or elevation of serum urea > 10% above ULN
12. Systolic blood pressure < 90 mmHg or >139 mmHg and/or diastolic blood pressure < 50 mmHg or > 89 mmHg (one repeat test will be acceptable in case of suspected white-coat hypertension)
13. Symptoms of arterial hypotension
14. Heart rate at rest outside the range of 50-90 beats per minute
15. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator
16. Increased risk of thrombosis, e.g. subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator
17. Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 24 grams alcohol/day (on average)
18. A positive result in the alcohol and/or urine drug screen at the screening visit
19. Smoking more than 5 cigarettes or the equivalent per day
20. Inability or unwillingness to refrain from smoking and use of nicotine substitute products one day before and during the inpatient period
21. Positive test for Hepatitis Bs antigen
22. Positive test for Hepatitis C antibodies. (Presence of Hepatitis C antibodies will not lead to exclusion if liver function tests are normal and a hepatitis C polymerase chain reaction is negative)
23. Positive result to the test for HIV-1/2 antibodies or HIV-1 antigen
24. Any medication (prescription and non-prescription drugs) within 7 days before IMP administration and/or anticoagulant therapy
25. Blood donation or blood loss of more than 500mL within the last 3 months
26. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation

Explanatory note on Exclusion Criterion 24: With the exception of paracetamol or NSAIDs for occasional use to treat acute pain, as judged by the Investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

36 participants in 3 patient groups

Gan & Lee Insulin Lispro Injection

Experimental group

Description:

Insulin lispro, 3 mL cartridge in prefilled pen, 100 units/mL (U-100)

Treatment:

Drug: Gan & Lee Insulin Lispro Injection

EU - approved Humalog ®

Active Comparator group

Description:

Insulin lispro (product approved and marketed in the EU), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)

Treatment:

Drug: Gan & Lee Insulin Lispro Injection

US - licensed Humalog ®

Active Comparator group

Description:

Insulin lispro (product approved and marketed in the US), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)

Treatment:

Drug: Gan & Lee Insulin Lispro Injection